135 related articles for article (PubMed ID: 12820322)
1. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
[TBL] [Abstract][Full Text] [Related]
2. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
3. Serum p53 autoantibodies in the follow-up of head and neck cancer patients.
Gottschlich S; Maune S; Maass JD; Görögh T; Hoffmann M; Hoffmann-Fazel A; Meyer J; Werner JA; Rudert H
Oncology; 2000 Jun; 59(1):31-5. PubMed ID: 10895064
[TBL] [Abstract][Full Text] [Related]
4. CYFRA 8/18 in head and neck cancer.
Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223
[TBL] [Abstract][Full Text] [Related]
5. Antibody responses to survivin and their clinical significance in patients with head and neck cancer.
Eto M; Kodama S; Uemura N; Suzuki M
Head Neck; 2007 Dec; 29(12):1128-35. PubMed ID: 17636541
[TBL] [Abstract][Full Text] [Related]
6. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
7. Head and neck cancer and p53-immunogenicity.
Maass JD; Gottschlich S; Goeroegh T; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2873-4. PubMed ID: 9329551
[TBL] [Abstract][Full Text] [Related]
8. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL
Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946
[TBL] [Abstract][Full Text] [Related]
10. p53 autoantibodies can be indicative of the development of breast cancer relapse.
Regele S; Vogl FD; Kohler T; Kreienberg R; Runnebaum IB
Anticancer Res; 2003; 23(1B):761-4. PubMed ID: 12680180
[TBL] [Abstract][Full Text] [Related]
11. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
Vogl FD; Frey M; Kreienberg R; Runnebaum IB
Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359
[TBL] [Abstract][Full Text] [Related]
12. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
[TBL] [Abstract][Full Text] [Related]
13. High rate of p53 overexpression in head and neck carcinomas detected with a refined ELISA.
Maass JD; Gottschlich S; Goeroegh T; Bruhn T; Lippert BM; Paulsen JI; Werner JA
Anticancer Res; 1997; 17(1A):473-8. PubMed ID: 9066697
[TBL] [Abstract][Full Text] [Related]
14. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
16. Inverse correlation between serum PGE2 and T classification in head and neck cancer.
Hambek M; Baghi M; Wagenblast J; Schmitt J; Baumann H; Knecht R
Head Neck; 2007 Mar; 29(3):244-8. PubMed ID: 17123309
[TBL] [Abstract][Full Text] [Related]
17. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
